Benjamin Leroy Jones

US Patent:

20080293696, Nov 27, 2008

Filed:

Jun 23, 2005

Appl. No.:

11/630850

Inventors:

Catherine Brennan - Durham NC, US
Julie A. Dixon - Bethany CT, US
William J. Scott - Guilford CT, US
Aniko Redman - Derby CT, US
Benjamin D. Jones - New Haven CT, US
Barton Phillips - New Haven CT, US
Philip Wickens - Wallingford CT, US
Istvan Enyedy - Milton MA, US
Ellalahewage Kumarasinghe - Hamden CT, US
Charles Kreiman - Wallingford CT, US
Jacques Dumas - Bethany CT, US
Uday Khire - Orange CT, US
Chih-Yuan Chuang - San Mateo CA, US
Harold C.E. Kluender - Trumbull CT, US
Zhenqiu Hong - Milford CT, US
Lei Wang - New Haven CT, US
Donald Bierer - Bethany CT, US

Assignee:

Bayer Pharmaceuticals Corporation - West Haven CT

International Classification:

A61K 31/55
C07D 405/12
A61K 31/4433
A61K 31/444
A61P 35/00
C07D 405/14
A61K 31/506

US Classification:

51421704, 5462824, 514338, 514333, 546256, 544333, 514256, 540597

Abstract:

A compound having the formula (1)in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A representswherein the group Rrepresents halogen, CF, or H, provided that the maximum number of CFgroups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R, Rand Rand the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.

US Patent:

20130225809, Aug 29, 2013

Filed:

Dec 20, 2012

Appl. No.:

13/722793

Inventors:

Bayer HealthCare LLC - , US
Catherine Brennan - Durham NC, US
Karl Miranda - Lexington MA, US
Brent Chandler - New Haven CT, US
Barton Phillips - New Haven CT, US
Jianmei Fan - Newton MA, US
Michael Brands - Wuppertal, DE
Andrea McClure - West Haven CT, US
Benjamin D. Jones - New Haven CT, US
Wenlang Fu - Milford CT, US
Donald Bierer - Bethany CT, US
Steven Magnuson - Wallingford CT, US
Harold C.E. Kluender - Trumbull CT, US

Assignee:

Bayer HealthCare LLC - Tarrytown NY

International Classification:

C07D 491/113
C07D 487/04

US Classification:

544112, 544183

Abstract:

This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

US Patent:

20220306634, Sep 29, 2022

Filed:

Jun 21, 2019

Appl. No.:

16/449123

Inventors:

- South San Francisco CA, US
Benjamin Jones - Cardiff-by-the-Sea CA, US
Betty Lam - San Diego CA, US
Masashi Takahashi - Chigasaki, JP
Christopher Smith - San Diego CA, US
Qing Dong - San Diego CA, US
Victoria Feher - San Diego CA, US
Zhe Nie - San Diego CA, US

International Classification:

C07D 487/04
C07D 471/04
A61K 31/519
A61K 31/527
A61K 45/06
C07D 487/10
A61K 31/437
C07D 519/00

Abstract:

Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

US Patent:

20180141951, May 24, 2018

Filed:

Aug 21, 2017

Appl. No.:

15/681953

Inventors:

- Osaka, JP
Benjamin Jones - Cardiff-by-the-Sea CA, US
Betty Lam - San Diego CA, US
Masashi Takahashi - Chigasaki, JP
Christopher Smith - San Diego CA, US
Qing Dong - San Diego CA, US
Victoria Feher - San Diego CA, US
Zhe Nie - San Diego CA, US

International Classification:

C07D 487/04
C07D 519/00
C07D 487/10
C07D 471/04
A61K 31/437
A61K 31/527
A61K 31/519
A61K 45/06

Abstract:

Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

US Patent:

20150336964, Nov 26, 2015

Filed:

Jul 31, 2015

Appl. No.:

14/814878

Inventors:

- Osaka, JP
Benjamin Jones - Cardiff-by-the-Sea CA, US
Betty Lam - San Diego CA, US
Christopher Smith - San Diego CA, US
Masashi Takahashi - Osaka, JP
Qing Dong - San Diego CA, US
Victoria Feher - San Diego CA, US
Zhe Nie - San Diego CA, US

Assignee:

TAKEDA PHARMACEUTICAL COMPANY LIMITED - Osaka

International Classification:

C07D 487/04
A61K 45/06
A61K 31/527
A61K 31/437
C07D 487/10
A61K 31/519
C07D 471/04

Abstract:

Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

US Patent:

20140207812, Jul 24, 2014

Filed:

Jan 23, 2014

Appl. No.:

14/162714

Inventors:

- Chicago IL, US
Donald John Frey - Gresham OR, US
Benjamin Sterling Jones - Beaverton OR, US

Assignee:

KCura Corporation - Chicago IL

International Classification:

G06F 17/30

US Classification:

707758

Abstract:

Methods and apparatus for collecting electronically stored information are disclosed. In general, a processor images an electronic device to collect metadata associated with a plurality of files stored on the electronic device. For example, the metadata may include file names, file sizes dates, etc. The processor then receives selection information associated with the metadata, the selection information being indicative of a subset of the plurality of files. The processor then installs an electronically stored information (ESI) collection application (e.g., remotely via a network and/or via a thumb drive exclusively in RAM) in the first electronic device (e.g., a device running one of several different operating systems) in response to a selection of a collection initiation trigger (e.g., selection of a hyperlink or virtual button). The processor then collects the ESI. For example, the processor may collect the ESI from a hard disk or solid state drive using a collection wizard user interface. The processor then receives the subset of the plurality of files.

US Patent:

20130245031, Sep 19, 2013

Filed:

May 2, 2013

Appl. No.:

13/886032

Inventors:

- Osaka, JP
Benjamin Jones - Cardiff-by-the-Sea CA, US
Betty Lam - San Diego CA, US
Christopher Smith - San Diego CA, US
Massashi Takahashi - Osaka, JP
Qing Dong - San Diego CA, US
Victoria Feher - San Diego CA, US
Zhi Nie - San Diego CA, US

Assignee:

Takeda Phamaceutical Company Limited - Osaka

International Classification:

C07D 487/04
A61K 45/06
A61K 31/527
A61K 31/519
C07D 519/00
C07D 487/10
C07D 471/04
A61K 31/437

US Classification:

514249, 514300, 5142651, 51425216

Abstract:

Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

US Patent:

20130116260, May 9, 2013

Filed:

Dec 17, 2010

Appl. No.:

13/518806

Inventors:

Yasuyoshi Arikawa - Osaka, JP
Benjamin Jones - Cardiff-By-The-Sea CA, US
Betty Lam - San Diego CA, US
Zhe Nie - San Diego CA, US
Christopher Smith - San Diego CA, US
Masashi Takahashi - Osaka, JP
Qing Dong - San Diego CA, US
Victoria Feher - San Diego CA, US

Assignee:

TAKEDA PHARMACEUTICAL COMPANY LIMITED - Osaka

International Classification:

A61K 31/527
A61K 45/06
C07D 471/04
C07D 487/10
C07D 487/04
A61K 31/519

US Classification:

514249, 544280, 5142651, 51425216, 544230

Abstract:

Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.